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Abstract
AIM
To evaluate the incidence of anastomotic strictures after 
intestinal resection in Crohn’s disease (CD), demon-
strate long-term efficacy and safety of endoscopic 
balloon dilation (EBD) in CD strictures and its impact on 
the diagnosis of subclinical postoperative endoscopic 
recurrence. 
METHODS
Retrospective single tertiary center study based on 
prospectively collected data between 2010 and 2015 
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including anastomotic and non-anastomotic strictures. 
RESULTS
29% of 162 CD patients included developed an 
anastomotic stricture. 43 patients with anastomotic 
strictures and 37 with non-anastomotic strictures 
underwent EBD; technical success was 97.7% and 
100%, respectively, however, 63% and 41% needed 
repeat dilation during the 4.4-year follow-up. Longer 
periods between surgery and index colonoscopy and 
higher lactoferrin levels were associated with the 
presence of stricture after surgery. Calprotectin levels 
> 83.35 µg/g and current or past history of smoking 
were associated with a shorter time until need for 
dilation (HR = 3.877, 95%CI: 1.480-10.152 and HR = 
3.041, 95%CI: 1.213-7.627). Anastomotic strictures 
had a greater need for repeat dilation (63% vs  41%, 
P  = 0.047). No differences were found between 
asymptomatic and symptomatic cohorts. Disease recur-
rence diagnosis was only possible after EBD in a third 
of patients. 
CONCLUSION
EBD is an effective and safe alternative to surgery, 
with a good short and long-term outcome, postponing 
or even avoiding further surgery. EBD may allow to 
diagnose disease recurrence in patients with no clinical 
signs/biomarkers of disease activity.
Key words: Crohn’s disease; Endoscopic recurrence; 
Anastomotic strictures; Non-anastomotic strictures; 
Endoscopic balloon dilation
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Core tip: This study evaluated the incidence of anas-
tomotic strictures after intestinal resection in Crohn’
s disease (CD), the long-term efficacy and safety of 
endoscopic balloon dilation (EBD) in CD strictures and 
its impact on the diagnosis of subclinical postoperative 
endoscopic recurrence. Almost one-third of CD patients 
developed an anastomotic stricture after ileocecal 
resection/right hemicolectomy. EBD was an effective 
and safe alternative to surgery, with a good short 
and long-term outcome, postponing or even avoiding 
further surgery. EBD also allowed to diagnose disease 
recurrence in patients with no clinical signs/biomarkers 
of disease activity. Longer intervals after surgery 
and higher lactoferrin levels were associated with 
anastomotic strictures; time until dilation was lower 
in patients with calprotectin levels > 83.35 µg/g and 
current/past history of smoking.
Lopes S, Rodrigues-Pinto E, Andrade P, Afonso J, Baron TH, 
Magro F, Macedo G. Endoscopic balloon dilation of Crohn’
s disease strictures-safety, efficacy and clinical impact. World J 
Gastroenterol 2017; 23(41): 7397-7406  Available from: URL: 
http://www.wjgnet.com/1007-9327/full/v23/i41/7397.htm  DOI: 
http://dx.doi.org/10.3748/wjg.v23.i41.7397
INTRODUCTION
Strictures in crohn’s disease (cD) develop during the 
course of the disease or as the presenting feature[1]. 
Up to 50% of cD patients undergo surgical resection 
within the first 10 years of diagnosis[2]. Disease 
recurrence often occurs at or above the anastomosis 
due to ongoing inflammatory activity[3,4]. This can result 
in luminal narrowing, and strictures (non-anastomotic 
and anastomotic), with up to 70% of patients requiring 
additional resection[5], though is unpredictable[6].
Medical therapy for stricture management is limited 
due to the fibrotic nature. Management includes surgical 
resection and stricturoplasty but with a high rate of 
recurrence and need for reoperation[7]. Increasing 
evidence supports endoscopic balloon dilation (EBD) as 
a safe and effective alternative to surgery, particularly 
for ileocecal and anastomotic strictures[8,9]. Technical 
and clinical success rates (resolution of obstructive 
symptoms) are seen in 73%-100% and 64%-70%, 
respectively, with a major adverse event (AE) rate 
of 2%-6.4%[1,10-12]. Balloon diameters of 25 mm are 
believed to increase risk of AEs[13]. During long-term 
follow-up patients needing surgery at 1, 3 and 5 years 
varies form 13%-17%, 28%-42%, and 36%-42% 
respectively. Strictures recur following dilation, and 
re-dilation may be required in up to 20% and 50% 
by 1 and 5 years, respectively[1,14,15]. The best results 
following dilation are obtained when stricture length is 
< 4 cm, and for anastomotic strictures when compared 
to de novo strictures[1,12,16].
Anastomotic strictures may represent disease 
recurrence, but data is limited and contradictory as 
to whether escalation of medical therapy following 
dilation may prevent the need for repeat dilation or 
surgery[10,12]. Other factors such as smoking status and 
disease activity status at the time of dilation may affect 
outcome of stricture dilation[12], though many studies 
are limited by short follow-up durations and small 
cohorts.
We sought to evaluate anastomotic stricture deve-
lopment after intestinal resection in cD and demonstrate 
long-term efficacy and safety of EBD in CD anastomotic 
and de novo strictures in a large referral centre cohort 
and determine the impact of dilation on the diagnosis of 
subclinical postoperative endoscopic recurrence.
MATERIALS AND METHODS
Retrospective single tertiary center study based on 
prospectively collected data from a clinical database 
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created for this purpose. Patients were treated 
from March 2010 to February 2015 including cD 
patients who had undergone ileocecal resection/right 
hemicolectomy. All patients were followed at our 
Inflammatory Bowel Disease (IBD) outpatient clinic 
and referred for endoscopic evaluation. Inclusion 
criteria were definitive diagnosis of cD established 
by clinical, radiographic, endoscopic, and histological 
criteria and previous surgery and surgical pathology. 
Exclusion criteria were previous EBD, age < 18 years, 
stricture length > 6 cm and fistulae or deep ulceration 
of the strictured segment.
clinical disease activity was assessed on the 
day of endoscopic examination, using the Harvey 
Bradshaw Index (HBI). clinically inactive disease was 
defined as a HBI < 5. Postoperative disease activity 
of the neoterminal ileum was evaluated according to 
the Modified Rutgeerts’ score[17]. Indication for EBD 
was to evaluate endoscopic recurrence or symptom/
biomarker-driven. 
cD patients with non-anastomotic strictures who 
underwent EBD during the study period were included 
as a control group (Figure 1).
All procedures were performed in an outpatient 
setting under propofol sedation, with cO2 insufflation, 
by one of two endoscopists (SL and ERP). Polyethylene 
glycol based bowel preparation was administered 
the day before colonoscopy. EBD was performed 
for strictures that would not allow passage with a 
colonoscope, regardless of patients’ symptoms. 
Dilations were performed endoscopically with a through-
the-scope balloon (Boston Scientific, Marlborough, MA), 
of 10-18 mm diameter and lengths of 55 mm. The 
balloon was filled with diluted contrast, with diameter of 
the balloon chosen according to endoscopist discretion. 
Inflation pressure was maintained for 2 min. 
Technical success was defined as the ability to 
pass the colonoscope through the stricture into the 
neoileum following dilation. clinical success was 
defined as improvement of obstructive symptoms (in 
symptomatic patients). Major AEs were defined as 
major bleeding (requiring surgery, blood transfusion or 
hospital admission) and perforation. Minor, self-limited 
bleeding was not considered an AE. All patients who 
underwent dilation were endoscopically reevaluated 
6-12 mo later. Long-term efficacy was defined as 
avoidance of surgical resection or repeat dilation 
after the initial dilation. Patients were followed until 
stricture resection, last clinic follow-up, or censor date 
of March, 2017. Escalation of medical therapy was 
defined as initiation of a thiopurine or anti-TNF within 6 
mo of first dilation, as determined by global physician 
assessment. 
All patients gave informed written consent to 
participate in the study that was approved by the 
Ethics committee of our Institution.
Statistical analysis
categorical variables were described through absolute 
and relative frequencies. continuous variables were 
described as median, minimum and maximum and 
dichotomized for analysis using the best cut-off on ROc 
analysis. Hypotheses were tested about the distribution 
of continuous variables with non-normal distribution, 
by using the nonparametric Mann-Whitney. The chi-
squared test and Fisher’s exact test were used for 
differences in proportions of patients experiencing a 
given outcome. Univariate and multivariate analysis by 
logistic regression was used to explore the correlation 
between predictor variables and need of dilation 
after surgery, as well as need to repeat dilation. To 
identify independent predictors of need of dilation 
after surgery, as well as need to repeat dilation, 
all significant variables evaluated in the univariate 
analysis were included. Kaplan-Meier survival analysis 
with log rank statistics was used to assess event-free 
survival, and cox conditional proportional hazards 
regression analysis was used to time-free survival. 
The results are shown as odds ratio (OR) and hazards 
ratio (HR) with 95% confidence intervals (CI). All the 
reported P values were two-sided, and P values of < 
0.05 were considered statistically significant. All data 
were arranged, processed and analyzed with SPSS® 
v.24.0 data (Statistical Package for Social Sciences).
RESULTS
Population
A total a 162 cD patients (52.5% males, n = 85) who 
had undergone ileocecal resection/right hemicolectomy 
were included; the mean age was 42.6 years (SD ± 
13.4 years). Baseline demographic characteristics are 
listed in Table 1. The median follow-up period since 
colonoscopy index was 4.4 years (1.3-6.8), with a 
median disease duration of 17.1 years (3.3-52.1). 
Median time between surgery and index colonoscopy 
was 7.7 years (range 0.3-37.6 years).
At the time of index colonoscopy, 82% of patients 
(n = 133) were receiving cD medication: 68.5% (n 
= 111) thiopurines and 36.4% (n = 59) anti-TNF 
medication; only 23% of the patients (n = 37) were 
on combination therapy. Seventeen percent of the 
patients (n = 27) had obstructive symptoms, with a 
median HBI of 1 (0-9). Median labs were: haemoglobin 
13.5 g/dL (9.6-18.3), albumin 42 g/dL (24.2-352), 
c-reactive protein 2.8 mg/L (0.1-105.3), median 
lactoferrin 4.7 µg/g (0.4-216) and median calprotectin 
68.5 µg/g (0.5-2051). 
Anastomotic strictures
Twenty-nine percent of patients (n = 47) had an 
anastomotic stricture (17 symptomatic), with 4 also 
having a non-anastomotic stricture; dilation wasn’t 
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= 2.6, 95%cI: 1.3-5.3, P = 0.007), longer duration 
between surgery and index colonoscopy [132 mo 
(9-439) vs 71 mo (3-415), P = 0.001], older age [47 
years (16-72) vs 39 years (18-77), P = 0.031] and 
lower c-reactive protein levels [2.65 mg/L (0.3-21.9) 
vs 2.85 mg/L (0.1-105.3), P = 0.045]. 
On univariate analysis, the presence of stricture 
after surgery was associated with longer periods 
between surgery and index colonoscopy (OR = 
1.006, 95%cI: 1.003-1.010, P = 0.001), higher 
lactoferrin levels (OR = 1.010, 95%cI: 1.000-1.021, 
P = 0.049), obstructive symptoms (OR = 6.155, 
95%cI: 2.546-14.880, P < 0.001), no medication 
with thiopurines (OR = 2.611, 95%cI: 1.282-5.319, 
P = 0.008) and older age at index colonoscopy (OR 
= 1.028, 95%cI: 1.002-1.055, P = 0.033) (Table 2). 
On multivariate analysis, only longer periods between 
surgery and index colonoscopy (OR = 1.007, 95%cI: 
1.001-1.013, P = 0.027) and higher lactoferrin levels 
(OR = 1.012, 95%cI: 1.000-1.024, P = 0.043) were 
associated with the presence of stricture (Table 2). 
In the cox regression univariate analysis, time 
until dilation was longer in patients on medication 
with thiopurines or anti-TNF (HR = 0.476, 95%CI: 
0.239-0.946, P = 0.034); in further subgroup analysis, 
thiopurine treatment was the only medication found 
to be significantly associated with a longer time to 
dilation (HR = 0.493, 95%cI: 0.275-0.883, P = 0.017). 
Obstructive symptoms and calprotectin levels higher 
than 83.35 µg/g, on the other hand, were associ-
ated with a shorter time until dilation (HR = 2.976, 
95%cI: 1.622-5.460, P < 0.001 and HR = 3.444, 
95%cI: 1.391-8.526, P = 0.008, respectively). There 
was a trend for current or past history of smoking 
being associated with a shorter time to dilation 
in the univariate analysis (HR = 1.752, 95%cI: 
0.964-3.185, P = 0.066). In the cox multivariate 
analysis, calprotectin levels > 83.35 µg/g and current 
performed in 4 patients: 1 due to stricture length > 6 
cm, 2 due to marked ulceration and 1 due to unstable 
scope position. 
The presence of stricture after surgery was 
associated with presence of obstructive symptoms 
(37% vs 9%, OR = 6.3, 95%cI: 2.5-14.9, P < 0.001), 
no medication with thiopurines (74.8% vs 53.2%, OR 
CD patients with prior ileocecal 
resection/hemicolectomy 
(n  = 162)
Anastomotic stricture 
(n  = 47)
Anastomosis without stricture 
(n  = 115)
CD patients with non-
anastomotic stricture 
(n  = 37)
Not dilated (n  = 4)
- Stricture length > 6 cm (n  = 1)
- Scope unstable position (n = 1)
- Marked ulceration (n  = 2)
Balloon dilation 
(n  = 43)
Balloon dilation 
(n  = 37)
Repeat dilation 
(n  = 27)
No further 
dilation 
(n  = 16)
Repeat dilation 
(n  = 15)
No further dilation 
(n  = 22)
Figure 1  Flowchart with study design.
Table 1  Baseline characteristics of crohn’s disease patients 
with prior ileocecal resection/right hemicolectomy
Characteristic CD (n  =  162)
Female/male (n) 77/85
Disease duration in years (median; min-max) 17.1 (3.3-52.1)
Follow-up time in years (median; min-max) 4.4 (1.3-6.8)
Time between surgery and index colonoscopy in years 
(median; min-max)
7.7 (0.3-37.6)
Age at index colonoscopy (mean; standard deviation) 42.6 (± 13.4)
Montreal classification (n; %)
   Age at diagnosis
      A1 25 (15.5)
      A2 116 (72)
      A3 20 (12.4)
   Disease location
      L1 89 (54.9)
      L2 9 (5.6)
      L3 55 (34)
      L1-4 7 (4.3)
      L3-4 2 (1.2)
   Behavior
      B1 6 (3.7)
      B2 77 (47.5)
      B3 79 (48.8)
   Perianal disease 38 (23.5)
Smoking habits (n; %)
   Non-smoker 86 (55.1)
   Ex-smoker 34 (21.8)
   Current smoker 36 (23.1)
Medication at index colonoscopy
   Thiopurines 111 (68.5)
   Anti-TNFα 59 (36.4)
TNFα: Tumor necrosis factor α.
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or past history of smoking were associated with a 
shorter duration to dilation (HR = 3.877, 95%cI: 
1.480-10.152, P = 0.006 and HR = 3.041, 95%cI: 
1.213-7.627, P = 0.018) (Figure 2).
Endoscopic balloon dilation
EBD was performed in 26.5% (n = 43) of patients 
(Table 3). Technical success was achieved in 97.7% (n 
= 42). Repeat dilation was required in 62.8% (n = 27) 
of patients (long-term efficacy: 37.2%), with a total of 
85 dilations being performed during the study period 
[median: 2 (1-5)], with a median balloon dilation of 
18mm (range 10-18). Technical success was achieved 
in 95.3% (n = 81) without major AEs, and only one 
episode of self-limited bleeding (1.2%). All patients 
(n = 17) had improvement of obstructive symptoms. 
Median time to second dilation was 453.5 d (range: 
152-1362).
Endoscopic recurrence, defined as modified Rut-
geerts score ≥ i2b was present in 60 patients (37.7%), 
of which 20 (33%) were diagnosed only after dilation 
of the anastomotic stricture. Following initial endoscopy 
and dilation, medical therapy was escalated in 38.5% 
of patients (n = 15; 3 began thiopurines and 14 began 
anti-TNF); however, escalation of medical therapy 
was probably driven by endoscopic recurrence (87%, 
n = 13) and not by anastomotic stricture presence, 
as suggested by escalation of therapy in 53% (n 
= 21) of the patients with endoscopic recurrence 
and no anastomotic stricture. No agreement was 
found between endoscopic recurrence and presence 
of stricture (K = 0.085, P = 0.273). Escalation of 
medical therapy did not decrease the need for repeat 
dilation; no other risk factors (gender, age, Montreal 
classification, perianal disease, smoking habits, 
previous medical therapy, presence of obstructive 
A
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Figure 2  Kaplan-Meier curves showing time from surgery to dilation (in mo) considering calprotectin levels (A) and smoking status (B).
Table 2  Univariate and multivariate analysis of risk factors for need for dilation after surgery
Risk factors Univariate analysis Multivariate analysis
OR 95%CI P  value OR 95%CI P  value
Significant in univariate and multivariate analysis  
   Time between surgery and index colonoscopy 1.006 1.003-1.010 0.001 1.007 1.001-1.013 0.027
   Lactoferrin levels 1.010 1.000-1.021 0.049 1.012 1.000-1.024 0.043
Significant in univariate analysis
   Subocclusive symptoms 6.155 2.546-14.880 < 0.001 - - 0.180
   No medical treatment with thiopurines 2.611 1.282-5.319 0.008 - - 0.500
   Age at index colonoscopy 1.028 1.002-1.055 0.033 - - 0.932
Not significant in univariate nor multivariate analysis
   Smoking status 1.877 0.912-3.861 0.087
      B2 behavior 1.221 0.619-2.408 0.565
      B3 behavior 0.895 0.454-1.767 0.750
      Perianal disease 1.376 0.632-2.996 0.421
   Anti-TNF therapy 0.893 0.443-1.799 0.751
   C-reactive protein levels 0.975 0.935-1.016 0.229
   Calprotectin levels 1.001 1.000-1.002 0.125
   Harvey-Bradshaw index 1.111 0.936-1.318 0.229
   Disease duration 1.002 1.000-1.005 0.089
OR: Odds ratio; CI: Confidence interval; B1: Non-stenosing and non-penetrating behaviour; B2: Stenosing behaviour; B1: Penetrating behaviour; TNF: 
Tumor necrosis factor.
Lopes S et al . Endoscopic dilation in CD
7402 November 7, 2017|Volume 23|Issue 41|WJG|www.wjgnet.com
symptoms, serum/fecal biomarkers) were found to 
influence need for repeat dilation. After initial dilation, 
4.6% of the patients (n = 2) required anastomotic 
stricture resection due to worsening or recurrence of 
symptoms. The median time to progression to surgery 
was 35 mo (33.4-36.7).
Non-anastomotic strictures
During the study period, a total of 37 cD patients 
(40.5% males, n = 15) underwent a total of 59 EBD 
sessions of non-anastomotic strictures (17 in the 
ileum, 13 in the ileocecal valve, 2 in the ascending 
colon, 1 in the transverse colon, 3 in the descending 
colon and 1 in the sigmoid colon) (Table 3). Twenty-
seven percent of the patients (n = 10) had obstructive 
symptoms, with a median HBI of 1 (0-10). Technical 
success was achieved in all patients (n = 37). Repeat 
dilation was required in 40.5% (n = 15) of patients 
(long-term efficacy: 59.5%), with a median balloon 
dilation of 16.5mm (range 10-18). Technical success 
and improvement in obstructive symptoms were 
achieved in all patients without AEs. Following EBD, 
medical therapy was escalated in 18.9% of patients 
(n = 7; 4 began thiopurines and 6 began anti-TNF). 
Median time to second dilation was 368 d (range: 
157-1705). Only 1 patient (3%) required surgical 
resection. No risk factors were found to influence need 
for repeat dilation.
Anastomotic strictures vs non-anastomotic strictures
Baseline characteristics of patients with anastomotic 
and non-anastomotic strictures are shown in Table 
3. Follow-up since 1st dilation was longer in patients 
with anastomotic strictures. Patients with anastomotic 
strictures had a greater recurrence of stenosis (63% vs 
41%, P = 0.047). In the univariate analysis, absence 
of thiopurine medication (OR = 3.1, 95%cI: 1.2-7.9, 
P = 0.019) and anastomotic strictures (OR = 2.5, 
95%cI: 1.01-6.1, P = 0.049) were the only factors 
found to influence need for repeat dilation.
Asymptomatic and symptomatic cohorts 
No statistical significant differences were found 
between asymptomatic and symptomatic cohorts 
when comparing baseline disease characteristics, 
medical therapy at time of dilation, disease activity, 
Table 3  Baseline characteristics comparison between anastomotic and non-anastomotic strictures n  (%)
Characteristic Anastomotic strictures (n  = 43) Non-anastomotic strictures (n  = 37) P  value
Female/male (n) 19/24 22/15 0.173
Disease duration in years (median; min-max) 19.2 (5.7-52.1) 16.3 (3.0-45.3) 0.236
Follow-up since 1st dilation in years (median; min-max) 4.4 (1.3-6.8) 2.9 (1.2-6.5) < 0.001
Time between 1st and 2nd dilation in days (median; min-max) 453.5 (152-1362) 368 (157-1705) 0.796
Age at index colonoscopy (mean; standard deviation) 44.9 (± 12.2) 39 (± 12.2) 0.035
Montreal classification
   Age at diagnosis 0.368
      A1 6 (14) 4 (12.9)
      A2 29 (67.4) 25 (80.6)
      A3 8 (18.6) 2 (6.5)
   Disease location 0.057
      L1 23 (53.5) 9 (29)
      L2 1 (2.3) 4 (12.9)
      L3 17 (39.5%) 14 (45.2%)
      L1-4 2 (4.7%) 3 (9.7%)
      L3-4 - 1 (3.2%)
   Behavior
      B1 1 (2.3) 4 (12.9) 0.071
      B2 22 (51.2) 19 (61.3) 0.387
      B3 20 (46.5) 8 (25.8) 0.07
   Perianal disease 12 (27.9) 9 (29) 0.916
Smoking habits 0.635
   Non-smoker 22 (52.4) 11 (44)
   Ex-smoker 8 (19) 9 (36)
   Current smoker 12 (28.6) 5 (20)
Medication at index colonoscopy
   Thiopurines 23 (53.5) 25 (67.6) 0.200
   Anti-TNFα 17 (39.5) 19 (51.4) 0.289
Obstructive symptoms 15 (35.7) 10 (27.8) 0.454
C-reactive protein 2.8 (0.3-18.4) 6.95 (0.2-35.5) 0.126
Calprotectin 103.5 (5.9-1356) 283 (166-321) 0.789
Lactoferrin 7.66 (1.05-204.4) 10.7 (7.1-22.7) 0.429
Need to repeat dilation 27 (62.8) 15 (40.5) 0.047
TNFα: Tumor necrosis factor α.
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EBD procedure, need for further dilations, escalation of 
medical therapy and need for surgery (Table 4).
DISCUSSION
cD is characterized by chronic, recurrent, transmural 
inflammation; intestinal strictures are believed to 
result from partial healing and localized fibrosis[18]. 
Strictures develop unpredictably after surgery[6]. EBD 
has emerged as a bridging tool for management of cD 
strictures with favorable success rates and efficacy[10].
In this study, we found that almost one-third of cD 
patients develop an anastomotic stricture after ileocecal 
resection/right hemicolectomy. The mean age at first 
dilation was 42.6 years, which reflects their etiology 
as a complication of the surgery. Longer intervals after 
surgery and higher lactoferrin levels were associated 
with anastomotic strictures; time until dilation was 
lower in patients with calprotectin levels > 83.35 µg/g 
and current/past history of smoking. Previous studies 
have not studied the development of anastomotic 
strictures after surgery, however, as a progressive 
disease, anastomotic strictures will be more likely over 
time. Both anastomotic and de novo strictures have 
either inflammatory and/or fibrotic elements. Healing 
occurs in a defined pattern during bouts of activity 
and remission, with progression to luminal narrowing 
leading to stricture formation[17]; on the other hand, 
elevated serologic markers probably reflect the 
inflammatory component of the neo terminal ileum 
instead of the presence of an anastomotic stricture. 
While there is controversy regarding the effect of 
smoking on the disease phenotype, literature supports 
smoking as a factor in complicated disease[19].
Regarding EBD, our technical success was 97.7%, 
similar to literature (88%-100%)[20] and similar to non-
Table 4  Baseline disease characteristics, endoscopic balloon dilation procedure, need for further dilations, escalation of medical 
therapy and need for surgery between asymptomatic and symptomatic cohorts n  (%)
Characteristic Asymptomatic strictures1 (n  = 53) Symptomatic strictures1 (n  = 25) P  value
Female/male (n) 25/28 16/9 0.165
Disease duration in years (median; min-max) 17.9 (2.9-45.3) 19.9 (5.3-52.1) 0.955
Follow-up since 1st dilation in years (median; min-max) 3.1 (1.3-6.8) 3.9 (2.1-6.7) 0.068
Time between 1st and 2nd dilation in days (median; min-max) 668 (157-2074) 877 (152-2242) 0.790
Age at index colonoscopy (mean ± SD) 41.7 ± 13.8 43 ± 9.3 0.425
Montreal classification 
   Age at diagnosis 0.998
      A1 7 (14) 3 (13.6)
      A2 36 (72) 16 (72.7)
      A3 7 (14) 3 (13.6)
   Disease location 0.319
      L1 22 (44) 9 (40.9)
      L2 5 (10) -
      L3 21 (42) 9 (40.9)
      L1-4 1 (2) 4 (18.2)
      L3-4 1 (2) -
   Behavior 0.833
      B1 4 (8) 1 (4.5)
      B2 28 (56) 12 (54.5)
      B3 18 (36) 9 (40.9)
   Perianal disease 15 (30) 6 (27.3) 0.815
Smoking habits 0.761
   Non-smoker 24 (52.2) 8 (42.1)
   Ex-smoker 8 (17.4) 4 (21.2)
   Current smoker 14 (30.4) 7 (36.8)
Previous surgery (ileocecal resection/right hemicolectomy) 27 (50.9) 15 (60) 0.454
Medication at index colonoscopy
Thiopurines 33 (62.3) 13 (52) 0.390
   Anti-TNFα 21 (39.6) 14 (56) 0.175
   Combo 13 (24.5) 9 (36) 0.293
C-reactive protein 6.2 (0.2-35.5) 3.2 (0.3-19.4) 0.351
Calprotectin 107 (18.2-837) 340 (5.9-1356) 0.449
Lactoferrin 7.1 (1.1-102.6) 37.6 (4.0-204) 0.071
Therapeutic success 52 (98.1) 25 (100%) 0.377
Balloon diameter (median; min - max) 18 (10-18) 18 (13.5-18) 0.201
Adverse events 0 (0) 1 (4) 0.129
Need to repeat dilation 27 (50.9) 15 (60) 0.454
Number of dilations (median; min - max) 2 (1-5) 2 (1-5) 0.463
Escalation of medical therapy after dilation 13 (27.7) 8 (34.8) 0.541
Need for surgery after dilation 2 (4) 1 (4.2) 0.973
1Two patients had no information regarding presence of obstructive symptoms (one in each group). TNFα: Tumor necrosis factor α.
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anastomotic strictures (100%), however, this was 
not associated with a permanent stricture dilation, as 
63% of patients with anastomotic strictures and 41% 
of those with non-anastomotic strictures required 
additional dilation over a 4.4-year period. The fibrotic 
pathology of anastomotic strictures may be responsible 
for the lower response rate of EBD for non-anastomotic 
strictures. Re-dilation was as technically successful, 
supporting the evidence that repeated dilations do 
not reduce the procedural efficacy[20,21]. The rate of 
major AEs, including bowel perforation and significant 
bleeding, has been reported to be between 2%-6%[1,8]. 
AEs have been attributed to balloon size (25 mm 
diameter), pressure used to dilate and number of 
dilations per session. Our data confirm safety of 
EBD for cD strictures. We had no serious AEs, which 
may be explained by the careful patient selection, 
fluoroscopy to evaluate stricture characteristics and 
monitoring, maximum balloon diameter of 18 mm, use 
of cO2 insufflation, and endoscopists experience.
Long-term outcome following EBD varies. In our 
study, a long-term efficacy of 37.2% for anastomotic 
strictures and 59.5% for non-anastomotic strictures 
was achieved during a follow-up period of 4.4 years. 
Even though follow-up was longer, results were 
somewhat inferior to previous studies (52%-69%) 
when considering only anastomotic strictures. 
However, EBD in previous studies was symptom-
driven, while in ours, EBD was performed for strictures 
that did not allow passage with a colonoscope, 
regardless of patients’ symptoms. Besides, EBD 
delayed time until surgery, with only 3 patients (2 with 
anastomotic and 1 with non-anastomotic strictures) 
requiring surgery during follow-up period, suggesting 
a benefit of EBD. A recent pooled analysis reported 
a technical success, clinical success, long-term 
symptomatic and surgical recurrence rates of 89%, 
81%, 48% and 29%, respectively[22]; these data are 
almost exclusively derived from retrospective cohort 
studies and may somewhat overestimate the actual 
benefit. In 2013, the European crohn’s and colitis 
Organisation stated that EBD was safe and effective 
and allowed surgery to be avoided in cD patients 
with anastomotic strictures[23]. The overall technical 
success rate in the meta-analysis performed by Hassan 
et al[8] was 86% (71%-100%), while 41% of patients 
required repeated EBD allowing an overall long-term 
clinical efficacy (avoidance of surgery) rate of 58% 
during a median follow up of 33 mo. 
Risk factors associated with need for subsequent 
dilation have been inconsistent. Longer disease 
duration was associated with a shorter time to repeat 
dilation[12]; technical success of dilation[8,24,25], length 
of stricture[8,26], and non-ulcerated stricture[27] were 
found to be associated with a successful procedure. 
In our study, the only factors found to influence need 
for repeat dilation (in the univariate analysis) were 
absence of thiopurine medications and anastomotic 
strictures. Escalation of medical therapy did not 
decrease the need for repeat dilation. considering 
therapeutic strategy, Thienpont et al[10] reported no 
significant effect of systemic medical therapy after 
dilation on redilation or surgery, while Honzawa et al[28] 
found that prior use of immunomodulatory drugs 
improved the clinical outcome of EBD for intestinal 
strictures in patients with cD. Patients in our study may 
also have had more severe disease, as demonstrated 
by the majority receiving immunossupressants at 
the time of index colonoscopy (immunomodulators: 
68.5%; biological therapy: 36.4%), as well as the 
high rate of repeat dilation. Despite the well-known 
deleterious association between tobacco use and cD 
activity, with increased risk of recurrence after surgery 
and EBD, we did not find any association between 
smoking and long-term outcome of EBD. Disease 
activity assessed by serologic markers, endoscopy, 
and clinical variables such as HBI, disease duration or 
time between surgery and dilation did not predict the 
need for repeat dilation, in accordance with previously 
published data[10,21].
It is controversial whether asymptomatic stric-
tures should be endoscopically treated. Previous 
studies have found no correlation between patient
´s symptoms and clinical scores and endoscopic/
radiographic findings after intestinal resection[29-31]. 
In our study, only 2 patients presented with an HBI 
> 7 and only 27 patients complained of obstructive 
symptoms, despite 47 having an anastomotic stricture. 
Serum biomarkers did not correlate with endoscopic 
recurrence or presence of strictures, supporting the 
belief that using only symptoms or c-reactive protein 
levels to make treatment decisions may increase the 
risk of disease progression and AEs. Our group believes 
that dilation of strictures, despite symptoms, has 
impact on patients’ management and disease course, 
allowing evaluation of disease activity and therapeutic 
adjustments. If EBD was not performed, a diagnosis of 
endoscopic recurrence would not have been possible 
in 33% of patients, all with normal biomarkers. On the 
other hand, we did not find any differences between 
asymptomatic and symptomatic cohorts regarding 
disease characteristics as well EBD peculiarities.
Limitations of our study include its retrospective 
nature, being conducted in a tertiary referral center 
(with referral or selection bias), lack of a control group 
(medical and surgical therapy), uncertainty of the 
degree of luminal narrowing caused by inflammation 
vs fibrosis and escalation of medical treatment biased 
toward those having active IBD. 
In conclusion, smoking habits and longer disease 
duration after surgery are associated with a higher risk 
of anastomotic strictures. EBD is a feasible, simple, 
effective and safe alternative to surgery, with the 
possibility of being repeated as needed, with excellent 
symptomatic response, as well as good short-term and 
long-term outcomes, postponing or avoiding surgery. 
Considering that a significant number of patients with 
significant strictures remain asymptomatic with normal 
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biomarkers, and the fact that the disease continues 
to evolve proximal to the strictures, we believe EBD 
should be considered for all strictures not transposable 
by a colonoscope, regardless of the presence or 
absence of symptoms, in order to adjust treatment in 
an attempt to alter the natural history of the disease. 
Thus, EBD is useful not only for symptom resolution 
but also for evaluating mucosal healing.
ARTICLE HIGHLIGHTS
Research background
Strictures in crohn’s disease (cD) develop during the course of the disease 
or as the presenting feature. More than half of cD patients will need surgery 
within the first 10 years of diagnosis. Medical therapy for stricture management 
is limited due to the fibrotic nature. Endoscopic balloon dilation (EBD) has been 
proposed as a safe and effective therapeutic intervention for cD strictures, 
particularly for ileocecal and anastomotic strictures. 
Research motivation
Data on long term efficacy and safety of EBD are limited due to lack of long-
term outcome and small cohorts. Up to now there are also some uncertainties 
regarding the factors associated with long term success rate. Smoking status 
and disease activity status at the time of dilation may affect outcome of stricture 
dilation, though many studies are limited by short follow-up durations and small 
cohorts. Furthermore, as the primary therapeutic goal of CD has shifted from 
clinical remission to achieving mucosal healing, it may be important to access 
the mucosa proximal to strictures to evaluate disease recurrence and escalate 
therapy if needed.
Research objectives
This study aimed to evaluate anastomotic stricture development after intestinal 
resection in CD and demonstrate long-term efficacy and safety center of EBD 
in CD anastomotic and de novo strictures in a large referral centre cohort and 
determine the impact of dilation on the diagnosis of subclinical postoperative 
endoscopic recurrence.
Research methods
CD patients who had undergone ileocecal resection/right hemicolectomy 
referred for endoscopic evaluation between March 2010 to February 2015 
were included in this study. CD patients with non-anastomotic strictures 
who underwent EBD during the study period were included as a control 
group. EBD was performed for strictures that would not allow passage with a 
colonoscope, regardless of patients’ symptoms. Technical success was defined 
as the ability to pass the colonoscope through the stricture into the neoileum 
following dilation. Clinical success was defined as improvement of obstructive 
symptoms (in symptomatic patients). All patients who underwent dilation were 
endoscopically reevaluated 6-12 mo later. Long-term efficacy was defined 
as avoidance of surgical resection or repeat dilation after the initial dilation. 
Patients were followed until stricture resection, last clinic follow-up, or censor 
date of March, 2017. Escalation of medical therapy was defined as initiation 
of a thiopurine or anti-TNF within 6 months of first dilation, as determined by 
global physician assessment. 
All data were prospectively collected in a database created for this 
purpose. After a 5 year follow up period all data were arranged, processed and 
analyzed with SPSS® v.24.0 data (Statistical Package for Social Sciences).
Research results
In this study we found that almost one-third of CD patients developed an 
anastomotic stricture after ileocecal resection/right hemicolectomy. Longer 
periods between surgery and index colonoscopy and higher lactoferrin levels 
were associated with the presence of stricture after surgery. calprotectin levels 
> 83.35 µg/g and current or past history of smoking were associated with a 
shorter time until need for dilation (HR = 3.877, 95%CI: 1.480-10.152 and 
HR = 3.041, 95%CI: 1.213-7.627). Technical success of EBD was 97.7% and 
100% for anastomotic and non-anastomotic strictures, respectively, and 63% 
and 41% of the patients needed repeat dilation during the 4.4-year follow-up. 
Anastomotic strictures had a greater need for repeat dilation (63% vs 41%, P 
= 0.047). No differences were found between asymptomatic and symptomatic 
cohorts. Disease recurrence was diagnosed only after EBD in a third of 
patients. 
Research conclusions
EBD is a feasible, simple, effective and safe alternative to surgery, with the 
possibility of being repeated as needed, with excellent symptomatic response, 
as well as good short-term and long-term outcomes, postponing or avoiding 
surgery. Considering that a significant number of patients with significant 
strictures remain asymptomatic with normal biomarkers, and the fact that the 
disease continues to evolve proximal to the strictures, we advocate EBD for 
all strictures regardless of the presence or absence of symptoms, in order to 
adjust treatment in an attempt to alter the natural history of the disease. Thus, 
EBD is useful not only for symptom resolution but also for evaluating mucosal 
healing.
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